The new plans are in addition to $21B that the drug manufacturer has already committed to U.S. research, development and ...

Gilead Sciences announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research ...

Gilead Sciences announced $11 billion in new planned investment in the U.S. to boost its domestic manufacturing and research ...

Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining ...

Businesses that are solid enough to perform well over extended periods, while consistently raising their payouts, are precisely what income investors should gravitate toward. Here are two corporations ...

Shares of Gilead Sciences Inc. GILD shed 1.27% to $96.91 Friday, on what proved to be an all-around dismal trading session ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

Shares of Gilead Sciences Inc. GILD rose 1.04% to $98.90 Wednesday, on what proved to be an all-around great trading session ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...